Oncolytics Biotech Inc. (NASDAQ:ONCY – Free Report) – Equities researchers at HC Wainwright increased their FY2024 earnings estimates for Oncolytics Biotech in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.28) per share for the year, up from their previous estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q1 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.41 EPS.
Other research analysts have also recently issued reports about the stock. Leede Financial cut shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.
Oncolytics Biotech Stock Performance
ONCY stock opened at $0.72 on Wednesday. The company’s 50 day moving average is $0.85 and its 200 day moving average is $0.97. Oncolytics Biotech has a 1-year low of $0.67 and a 1-year high of $1.53.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncolytics Biotech stock. Vantage Point Financial LLC purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY – Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 29,744 shares of the company’s stock, valued at approximately $27,000. 6.82% of the stock is owned by hedge funds and other institutional investors.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- What is the S&P/TSX Index?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Insider Trades May Not Tell You What You Think
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Pros And Cons Of Monthly Dividend Stocks
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
